GlobeNewswire Inc | Aug 31, 2020 08:00AM EDT

August 31, 2020

NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (AzurRx or the Company), a company specializing in the development of non-systemic, recombinanttherapies forgastrointestinal diseases, today announcedthat it will be making company presentations at two upcoming investor conferences: the 2020 H.C. Wainwright 22nd Annual Global Investment Conference on Monday, September 14that 4:30 p.m. Eastern Time and the 2020 LD 500 Virtual Conference on Friday, September 4th at 11:40 a.m. Eastern Time.

AzurRx CEO and President James Sapirstein will be presenting to a live virtual audience and will be participating in one-on-one meetings with investors who are registered to attend the two conferences.

About AzurRx BioPharma, Inc.AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a biopharmaceutical companyspecializedin the research and development of non-systemic biologics forgastrointestinal disorders. The Company is focused on the development of its lead drugcandidate, MS1819. AzurRx is currently conducting two Phase 2clinical trialsof MS1819: the OPTION 2 monotherapy trial, and the Combination therapy trial,consistingof MS1819 in conjunction with porcine-derivedpancreatic enzyme replacement therapy, the current standard of care. The Company is headquartered in New York, NY, with scientific operations based in Langlade, France and clinical operations in Hayward, California. Additional information on the Company can be found atwww.azurrx.com.

Forward-Looking StatementsThis press release may contain certain statements relating to future results which are forward-looking statements. These statements are not historical facts, but instead represent only the Companys belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Companys control. It is possible that the Companys actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, including whether results obtained in preclinical and nonclinical studies and clinical trials will be indicative of results obtained in future clinical trials; whether preliminary or interim results from a clinical trial such as the interim results presented will be indicative of the final results of the trial. Additional information concerning the Company and its business, including a discussion of factors that could materially affect the Companys financial results, including those related to the clinical development of MS1819, the results of its clinical trials, and the impact of the coronavirus (COVID-19) pandemic on the Companys operations and current and planned clinical trials, including, but not limited to delays in clinical trial recruitment and participation are contained in the Companys Annual Report on Form 10-K for the year ended December 31, 2019 under the headingRisk Factors,as well as the Companys subsequent filings with the Securities and Exchange Commission. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

For more information:

AzurRx BioPharma, Inc. 760 Parkside Avenue, Suite 304 Brooklyn, NY 11226 Phone: (646)-699-7855info@azurrx.com

Investor Relations contact:

LifeSci Advisors, LLC. Hans Vitzthum, Managing Director 1 International Place, Suite 1480 Boston, MA 02110 Phone: 617-430-7578hans@lifesciadvisors.com